Profile of Immunoglobulin G and IgM Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
-
Authors
-
-
Qu, Jiuxin1
-
Wu, Chi1
-
Li, Xiaoyong1
-
Zhang, Guobin1
-
Jiang, Zhaofang1
-
Li, Xiaohe2
-
Zhu, Qing1
-
Liu, Lei3
-
1
Department of Clinical Laboratory, The Third People's Hospital of Shenzhen, Southern University of Science and Technology, National Clinical Research Center for Infectious Diseases, Shenzhen, China.
,
(China)
-
2
Department of Infectious Diseases, The Third People's Hospital of Shenzhen, Southern University of Science and Technology, National Clinical Research Center for Infectious Diseases, Shenzhen, China.
,
(China)
-
3
The Third People's Hospital of Shenzhen, Southern University of Science and Technology, National Clinical Research Center for Infectious Diseases, Shenzhen, China.
,
(China)
- Type
- Published Article
- Journal
-
Clinical Infectious Diseases
- Publisher
-
Oxford University Press
- Publication Date
-
Nov 19, 2020
- Volume
-
71
- Issue
-
16
- Pages
-
2255–2258
- Identifiers
-
DOI: 10.1093/cid/ciaa489
-
PMID: 32337590
- Source
-
Medline
- Keywords
-
- Language
-
English
- License
-
Unknown
Abstract
We profiled the serological responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein and spike (S) glycoprotein. The majority of the patients developed robust antibody responses between 17 and 23 days after illness onset. Delayed, but stronger, antibody responses were observed in critical patients. © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: [email protected]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 12/04/2020 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at
https://www.ncbi.nlm.nih.gov/pubmed/32337590
